We next tested other possible clinical, oncological (BRAF/NRAS status, stage, LDH levels, presence of metastasis), virological or hepatological characteristics of our patient cohorts that might contribute to ICB-hepatitis during dural checkpoint therapy in the pooled cohort (Additional file 1: Table S3). This evidence concerns the gene BRAF and hepatitis A virus infection.